Semaglutide targets MASH molecular pathways beyond weight loss.

作者信息

Michel Maurice, Schattenberg Jörn M

机构信息

Department of Internal Medicine II, University Medical Centre Saarland, Homburg, Germany.

Faculty of Medicine, Saarland University, Saarbrücken, Germany.

出版信息

Nat Med. 2025 Sep 1. doi: 10.1038/s41591-025-03927-w.

DOI:10.1038/s41591-025-03927-w

PMID:40890553

Abstract

摘要

相似文献

[1]

Semaglutide targets MASH molecular pathways beyond weight loss.

Nat Med. 2025-9-1

[2]

Semaglutide improves metabolic dysfunction-associated steatohepatitis: A 10-year retrospective study.

JGH Open. 2024-2-22

[3]

Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese hamster models of MASH and MetALD.

Eur J Pharmacol. 2025-9-15

[4]

Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis.

Nat Med. 2025-7-21

[5]

Diabetes Obes Metab. 2025-2

[6]

Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?

J Gastroenterol Hepatol. 2025-9

[7]

Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Dig Dis Sci. 2025-1

[8]

Effects of weight loss from oral semaglutide administration on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a retrospective analysis using propensity score matching.

Diabetol Int. 2024-7-31

[9]

Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.

Hepatology. 2025-2-4

[10]

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

N Engl J Med. 2025-6-5

本文引用的文献

[1]

Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis.

Nat Med. 2025-7-21

[2]

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

N Engl J Med. 2025-6-5

[3]

Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis.

J Hepatol. 2025-3-7

[4]

A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures.

Nat Metab. 2023-4

[5]

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.

Lancet Gastroenterol Hepatol. 2023-6

[6]

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.

N Engl J Med. 2021-10-21

[7]

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

N Engl J Med. 2021-3-25

[8]

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease.

Contemp Clin Trials. 2020-11

[9]

The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.

J Hepatol. 2015-6-19

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Semaglutide targets MASH molecular pathways beyond weight loss.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

本文引用的文献